Promedior, a clinical stage biotechnology company has raised $21.5M in a first closing of a Series D financing round. The financing was led by a new investor, Fibrotec Ventures with participation from all of Promedior’s existing venture investors, including Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group. This [...]

Malvern, Penn.-based Promedior Inc., a clinical stage biotechnology company developing therapeutics for fibroproliferative diseases, has held a $21.5 million first closing of its Series D round.  New investor Fibrotec Ventures led the round, which included existing shareholders Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group. This new round [...]

Catalyst Biosciences Inc. has sealed a $7 million milestone payment from Pfizer, as part of a research and license agreement between the two companies. Catalyst recently initiated Phase 1 clinical trials for one of its products, designed to help treat hemophilia patients. Privately held Catalyst is backed by investors including Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures, RCT BioVentures and Sofinnova Ventures.

Woburn, Mass.-based PathoGenetix Inc. has raised $7.5 million in a second closing of its Series B financing round. The company announced a $4 million first closing of the round in August. The latest installment brings the Series B total to $11.5 million. Investors include Ascension Health Ventures, Excel Venture Management, CB Health Ventures, and HealthCare Ventures. PathoGenetix develops genome sequence scanning technology.

Sensors for Medicine and Science Inc., a Maryland-based medical device company, has raised $54.1 million in Series D financing. New investors Delphi Ventures led the round, which included participation from existing shareholders New Enterprise Associates, HealthCare Ventures, Anthem Capital and Greenspring Associates.

Theraclone Sciences Inc. has added $10.6 million to its Series B round, closing the financing with a total of $41 million. ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures and Zenyaku Kogyo participated in the financing. The money will be used to continue clinical and discovery programs.

Cleveland Heartlab has closed an $18.4 million Series B round. Excel Venture Management and HealthCare Ventures, both of Boston, led the round. Existing investors also participated.

Woburn, Mass.-based PathoGenetiX Inc., a developer of genome sequence scanning technology, has raised $4 million in a first close of its Series B financing. Excel Venture Management led the round, which also included investments from CB Health Ventures and HealthCare Ventures. The company has sealed commitments for $9.5 million in total Series B financing.

nanoMR Inc. has closed on $13 million from Excel Venture Management, Healthcare Ventures, vSpring Capital, The Dow Chemical Company, and Sun Mountain Capital. Steven Gullans of Excel and Gus Lawlor of Healthcare Ventures will join the board as a result of the round. The money will help nanoMR to develop commercial instruments for the clinical microbiology market, perform clinical studies and prepare for product launch, the company said in a release.

Radius Health Inc. said Tuesday that it closed a $91 million third round of financing. The round includes $66 million in equity financing, and a commitment by GE Capital, Healthcare Financial Services and Oxford Finance for a $25 million multi-draw term loan facility. Five new investors–including BB Biotech AG, Brookside Capital, Saints Capital, Nordic Bioscience, and Ipsen Pharma SAS–joined existing investors MPM Capital, BB Biotech Ventures, MPM Bio IV NVS Strategic Fund, The Wellcome Trust, HealthCare Ventures, and Scottish Widows Investment Partnership in the equity portion of the round. Radius Health is based in Cambridge, Mass. Radius also announced that immediately following the initial closing of the financing, it merged with MPM Acquisition Corp., an unlisted public reporting shell company. The combined company will go by the name Radius Health. Radius is a developer of drug therapies for osteoporosis and women’s health.